Article

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA.
Breast Cancer Research and Treatment (Impact Factor: 3.94). 11/2008; 116(3):595-602. DOI: 10.1007/s10549-008-0200-5
Source: PubMed

ABSTRACT

For patients with axillary lymph node-negative breast cancer, benefits from adjuvant therapy are smaller than in node-positive disease and thus more selective use is warranted, prompting development of risk profiling to identify those most likely to benefit. Examination of the magnitude and changes in the hazard of failure over time in node-negative breast cancer may also be informative in this regard.
Among 9,444 participants from five randomized trials (accrual 1982-1998) investigating chemotherapy and tamoxifen for node-negative breast cancer, we estimated recurrence hazards over time by tumor estrogen receptor (ER) status and adjuvant treatment.
In patients treated by surgery only, we observed the previously noted larger hazard peak followed by a rapid decrease in ER-negative patients and smaller but more persistent hazard in ER-positive patients. After approximately 48 months, the ER-positive hazard is greater. For adjuvant treatment, while tamoxifen decreases the early hazard in ER-positive patients to that of the chemotherapy-treated ER-negative group, in later follow-up (beyond 5 years) the hazard for ER-positive patients again exceeds that of ER-negative patients. Adding chemotherapy to tamoxifen in ER-positive patients results in large early hazard reduction, but in later follow-up the hazard converges with those of patients treated by surgery only or tamoxifen.
Recurrence hazards over time reveal changes in risk that may have biologic and therapeutic strategy relevance. In ER-negative tumors, a large early chemotherapy benefit is followed by a consistently low recurrence hazard over time. In ER-positive patients, the chemotherapy benefit appears concentrated mostly in earlier follow-up, and a greater recurrence risk remains.

Download full-text

Full-text

Available from: Stewart J Anderson, Mar 20, 2014
  • Source
    • "Using an immunohistochemical examination of the amounts of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and Ki-67 expression which reflects cellular proliferation, breast cancers are classified into several subtypes[1]. Breast cancer subtypes have differ-ent clinical features, including different prognoses and responses to therapies12345. Therefore, non-invasive prediction of subtype using magnetic resonance imaging (MRI) is a desirable approach for selecting therapies. Several reports have compared diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) values in addition to the morphological characteristics on MRI with various pathological findings and biomarkers of breast cancer67891011. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To compare the morphology and minimum apparent diffusion coefficient (ADC) values among breast cancer subtypes. Methods: Ninety-three patients, who underwent breast MRI and collectively had 98 pathologically proven invasive carcinomas, were enrolled. Morphology was evaluated according to BIRADS-MRI. Minimum ADC was measured. Morphology and minimum ADC were compared among subtypes. Multivariate logistic regression analyses were used to identify the characteristics associated with different subtypes. Results: Oval/round shape was significantly associated with triple-negative (TN) cancer (TN vs. non-TN: 90.9% vs. 45.2%; p=0.0123). Rim enhancement was significantly less frequent in Luminal A (Luminal A vs. non-Luminal A: 34.2% vs. 76.1%; p=0.0003). The minimum ADC of Luminal A was significantly higher than that of Luminal B (HER2-negative) (834 vs. 748×10(-6)mm(2)/s; p<0.025). The minimum ADC of the TN-special type was significantly higher than that of TN-ductal (997 vs. 702×10(-6)mm(2)/s; p<0.025). On the multivariate analysis comparing the characteristics associated with Luminal A vs. Luminal B (HER2-negative), the internal enhancement characteristics of the mass and minimum ADC were significant factors. Conclusion: Morphology and minimum ADC would be useful in distinguishing breast cancer subtypes.
    Full-text · Article · Nov 2015 · European journal of radiology
  • Source
    • "This could explain why it is not significant for the complete follow-up period. The time-varying effect of the variable HR+ has also been pointed out in Dignam et al. (2009) and Hilsenbeck et al. (1998). This PHs assumption is satisfied when we divided the follow-up period into two periods: 0–5 years and 5–20 years. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Individuals may experience more than one type of recurrent event and a terminal event during the life course of a disease. Follow-up may be interrupted for several reasons, including the end of a study, or patients lost to follow-up, which are noninformative censoring events. Death could also stop the follow-up, hence, it is considered as a dependent terminal event. We propose a multivariate frailty model that jointly analyzes two types of recurrent events with a dependent terminal event. Two estimation methods are proposed: a semiparametrical approach using penalized likelihood estimation where baseline hazard functions are approximated by M-splines, and another one with piecewise constant baseline hazard functions. Finally, we derived martingale residuals to check the goodness-of-fit. We illustrate our proposals with a real dataset on breast cancer. The main objective was to model the dependency between the two types of recurrent events (locoregional and metastatic) and the terminal event (death) after a breast cancer.
    Full-text · Article · Nov 2013 · Biometrical Journal
  • Source
    • "Az emlőrák prognózisát és gyógyszeres kezelésének stratégiáját alapvetően a daganat biológiai tulajdonságai és kiterjedtsége határozzák meg [3] [4] [5] [6] [7] [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Healthy lifestyle, population-based screening mammography and modern medical-oncological treatment in specialized breast cancer centers are the basic elements of the fight against breast cancer mortality. Treatment plan for the individual patient should be recommended by multidisciplinary oncoteam before initiating definitive therapy. Strategy of the medical-oncological therapy of breast cancer is determined by the biological features and stage of the tumor. The most important biological features are endocrine sensitivity, Human Epidermal Growth Factor Receptor 2 status and proliferative capability of the tumor. In this review the strategy of medical-oncological treatment (chemotherapy, endocrine therapy, targeted biological therapy) of breast cancer is presented, based on receptor status and proliferative capability of the tumor in various stages of the disease.
    Full-text · Article · Jan 2012 · Orvosi Hetilap
Show more